Trial Review

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been endorsed by the ANZCTR. Before participating in a study, talk to your health care provider and refer to this information for consumers
Trial details imported from ClinicalTrials.gov

For full trial details, please see the original record at https://clinicaltrials.gov/ct2/show/NCT00334009




Registration number
NCT00334009
Ethics application status
Date submitted
5/06/2006
Date registered
6/06/2006
Date last updated
6/03/2008

Titles & IDs
Public title
Catecholamine-O-Methyl-Transferase(COMT)-Polymorphism in Cardiac Surgery
Scientific title
Impact of Catecholamine-O-Methyl-Transferase Enzyme Activity on Clinical and Biological Parameters in Patients After Cardiac Surgery.
Secondary ID [1] 0 0
H2005/02320
Universal Trial Number (UTN)
Trial acronym
Linked study record

Health condition
Health condition(s) or problem(s) studied:
Cardiac Surgery 0 0
Condition category
Condition code

Intervention/exposure
Study type
Observational
Patient registry
Target follow-up duration
Target follow-up type
Description of intervention(s) / exposure
Comparator / control treatment
Control group

Outcomes
Primary outcome [1] 0 0
duration of vasoplegia and incidence of acute renal failure following cardiopulmonary bypass
Timepoint [1] 0 0
Secondary outcome [1] 0 0
length of stay in intensive care and in hospital, requirement of renal replacement therapy, mortality
Timepoint [1] 0 0

Eligibility
Key inclusion criteria
- Patients undergoing elective cardiac surgery (in whom CPB is planned) at the Austin
Hospital and Warringal Private Hospital.
Minimum age
18 Years
Maximum age
No limit
Sex
Both males and females
Can healthy volunteers participate?
No
Key exclusion criteria
- Intake of Levodopa

- Intake of COMT inhibitors (e.g. Entacapone, Tolcapone)

- Intake of monoamino oxidase inhibitors type A and B (e.g. Moclobemide, Selegiline,
Rasagiline)

- Patients below 18 years of age

- oral steroids

- emergency patients (cardiac symptoms occurred < 24 hours prior to operation)

- patients receiving IV nitrates/nitroprusside sodium

Study design
Purpose
Duration
Selection
Timing
Prospective
Statistical methods / analysis

Recruitment
Recruitment status
Completed
Data analysis
Reason for early stopping/withdrawal
Other reasons
Date of first participant enrolment
Anticipated
Actual
1/06/2006
Date of last participant enrolment
Anticipated
Actual
Date of last data collection
Anticipated
Actual
Sample size
Target
Accrual to date
Final
Recruitment in Australia
Recruitment state(s)
VIC
Recruitment hospital [1] 0 0
Austin Hospital - Melbourne
Recruitment postcode(s) [1] 0 0
3084 - Melbourne

Funding & Sponsors
Primary sponsor type
Other
Name
Austin Health
Address
Country

Ethics approval
Ethics application status

Summary
Brief summary
Although clinical risk factors for postoperative development of vasodilatory shock and acute
renal failure have been identified; there is a considerable proportion of patients undergoing
cardiac surgery where this syndrome cannot be predicted.

We sought to investigate the impact of Catecholamine-O-Methyltransferase (COMT) polymorphism
on the duration of vasodilatory shock and other important clinical outcomes in cardiac
surgery patients.

COMT is a key enzyme in the degradation of catechols eg. catecholamines. 25% of the
population have a low activity (L/L) of this enzyme. Sustained low COMT activity is
associated with an altered metabolic profile of catecholamines and their degradation
products.

The process of cardiopulmonary bypass (CPB)over-activates some of the same mechanisms the
body uses to defend itself against severe infection. One of the main overactive defence
mechanisms is the release of highly toxic compounds derived from oxygen - a process called
'oxidative-stress'. Increased reactive oxygen species (ROS) generation can lead to
inactivation of biologic mediators, including catecholamines. It is well established that
some radicals autoxidizes catecholamines, including DA, NE, and epinephrine and contribute
significantly to vasoplegia.

As part of this study, we will take six 2.7mL samples of blood, collected before, and after
the operation, from the arterial catheter routinely inserted in every patient. This blood
will be used to measure COMT genotype, the concentration of plasma-catecholamines as well as
marker of oxidative stress.

Our plan is to enrol patients undergoing cardiac surgery if the use of the CPB is planned.
Trial website
https://clinicaltrials.gov/ct2/show/NCT00334009
Trial related presentations / publications
Public notes

Contacts
Principal investigator
Name 0 0
Rinaldo Bellomo, MD, FRACP
Address 0 0
Austin Health
Country 0 0
Phone 0 0
Fax 0 0
Email 0 0
Contact person for public queries
Name 0 0
Address 0 0
Country 0 0
Phone 0 0
Fax 0 0
Email 0 0
Contact person for scientific queries



Summary Results

For IPD and results data, please see https://clinicaltrials.gov/ct2/show/NCT00334009